BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23716027)

  • 1. The prognostic relevance of psammoma bodies and ultrasonographic intratumoral calcifications in papillary thyroid carcinoma.
    Pyo JS; Kang G; Kim DH; Park C; Kim JH; Sohn JH
    World J Surg; 2013 Oct; 37(10):2330-5. PubMed ID: 23716027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
    Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
    PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma: A Large Case-control Study.
    Cai YF; Wang QX; Ni CJ; Guo GL; Li Q; Wang OC; Wu L; Du HY; You J; Zhang XH
    Medicine (Baltimore); 2015 Nov; 94(44):e1881. PubMed ID: 26554782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular variant of papillary thyroid carcinoma with B-type Raf(V600E) showing higher frequency of suspicious sonographic features and multifocality.
    Shin DY; Kim KJ; Chang S; Kim H; Hwang S; Kim W; Bae J; Park S; Kang SW; Chung WY; Lee EJ
    Head Neck; 2015 Nov; 37(11):1590-5. PubMed ID: 24909403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
    Pyo JS; Kang G; Kim DH; Chae SW; Park C; Kim K; Do SI; Lee HJ; Kim JH; Sohn JH
    Pathol Res Pract; 2013 Apr; 209(4):228-32. PubMed ID: 23528368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of multifocality in papillary thyroid carcinoma.
    Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
    Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
    Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterosuperior lesion has a high risk of lateral and central nodal metastasis in solitary papillary thyroid cancer.
    Lee DJ; Lee KH; Kim JH; Kwon KH; Yoon DY; Rho YS
    World J Surg; 2015 Feb; 39(2):387-92. PubMed ID: 25331728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
    Li C; Lee KC; Schneider EB; Zeiger MA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?
    Ito Y; Yoshida H; Kihara M; Kobayashi K; Miya A; Miyauchi A
    World J Surg; 2014 Mar; 38(3):679-87. PubMed ID: 24052184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.